+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
ID07545512

Identification of Risk Markers for Sudden Cardiac Death in Patients with Moderately Reduced Left Ventricular Function After Ischemic Heart Attack Using Implantable Loop Recorder Monitoring

Led by University Hospital, Clermont-Ferrand · Updated on 2026-10-28

400

Participants Needed

15

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating risk markers for sudden cardiac death SCD in patients who have ischemic heart disease with moderately impaired left ventricular ejection fraction LVEF between 35% and 50%. Despite advances in treatment after myocardial infarction, the risk of sudden death remains a major concern, especially in those with complications such as ventricular arrhythmias and myocardial scarring. Current risk assessment mainly relies on LVEF below 35%, which is not sufficient for patients with moderately reduced LVEF. This study aims to develop a predictive risk score for sudden death in this group. Participants who had a STEMI heart attack at least 40 days prior with LVEF between 35% and 50% will undergo various examinations including cardiac MRI, echocardiography, ECG, Holter monitoring, blood and genetic sampling, and implantation of an implantable loop recorder ILR device for continuous heart rhythm monitoring with remote monitoring. These assessments will provide data to create a risk prediction score. Patients will be followed clinically and by remote monitoring for up to 60 months. Throughout the study, participants will have annual cardiology visits including clinical exams, ECG, echocardiography, and blood tests. The implantable loop recorder will continuously monitor heart rhythms to detect arrhythmias. Researchers will track occurrences of sudden cardiac death, malignant ventricular arrhythmias, and other related events to evaluate potential predictive markers. The study includes safety monitoring and prohibits certain antiarrhythmic drugs except beta-blockers during follow-up.

CONDITIONS

Brief Title

ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY

Research Team

L

Lise Laclautre

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here